Last reviewed · How we verify

NCT06898320

Cardiac Injury Due to Anthracycline in Paediatric Oncological Patients

Recruiting now Last updated 9 May 2025
What this trial tests

trial in Heart Injuries in 22 participants. Currently enrolling.

Timeline
21 July 2023
Primary endpoint
21 July 2033
21 July 2033

Quick facts

Lead sponsorIRCCS Burlo Garofolo
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment22
Start date21 July 2023
Primary completion21 July 2033
Estimated completion21 July 2033
Sites1 location across Italy

Conditions studied

Sponsor

IRCCS Burlo Garofolo — full company profile →

Who can join

Adults 0 to 18, any sex, with Heart Injuries or Anthracycline. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study investigates the role of echocardiography and of serum biomarkers (NT-proBNP, cardiac Troponin-I) in predicting cardiac injury in a cohort of paediatric oncological patients treated with Anthracycline chemotherapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other IRCCS Burlo Garofolo trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06898320.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing